Pfizer's rebound is well underway.

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva’s Lyme disease ...

Income investors shouldn't be too worried about the pharma giant cutting its dividend.

Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find ...

Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage ...

Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are ...

When Pfizer was coming out of the COVID-induced growth phase in early 2024, I turned bullish alongside CEO Albert Bourla, effectively betting his pension on Pfizer stock. Since then, Pfizer has proven ...

Pfizer Inc. PFE shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat. Here’s what investors need to know. Dave Denton is set to ...

Pfizer Inc. (PFE), headquartered in New York, is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines. With a market cap of $140.6 ...

ast June, when AI drug discovery startup Chai Discovery was just 15 months old, it released a new model that could design antibodies. Nearly 20 pharma companies reached out to talk. “It was like we ...

It must have been a pretty good few months for Pfizer investors (PFE) as the stock surprisingly outperformed the S&P 500 (SPX) (SPY) during this period since I last updated PFE in May. In my previous ...